Two Options the sweetest among them is bitter: Fournier-gangrene associated with sodium-glucose co-transporter 2-inhibitors


Two Options the sweetest among them is bitter: Fournier-gangrene associated with sodium-glucose co-transporter 2-inhibitors


Awad Magbri, MD, FACP, Mariam El-Magbri, BSC, MPH, Kamran Suljuki, PharmD, MBA, Shaukat Rashid, MD.

Regency Vascular Access, Toledo, OH


Global Journal of Urology and Nephrology

The authors discuss a case of sodium-glucose co-transporter 2 inhibitor associated with Fournier-gangrene in a patient with type-2 diabetes millets. The patient had extensive surgical intervention and skin graft but succumbed to her disease.


Keywords: Fournier’s gangrene, diabetes, perineum infection, sodium-glucose cotransporter-2 inhibitors, glycosuria.

Free Full-text PDF


How to cite this article:
Awad Magbri, Mariam El-Magbri, Kamran Suljuki, Shaukat Rashid.Two Options the sweetest among them is bitter: Fournier-gangrene associated with sodium-glucose co-transporter 2-inhibitors. Global Journal of Urology and Nephrology, 2019, 2:13. DOI:10.28933/gjun-2019-06-2605


References:
1. Fournier JA. Gangrène foudroyante de la verge. Semaine Med 1883; 3: 345-348
2. Pastore AL, Palleschi G, Ripoli A, et al. A multi step approach to manage Fournier’s gangrene in a patient with unknown type II diabetes: surgery, hyperbaric oxygen, and vacuum-assisted closure therapy: a case report. J Med Case Rep. 2013; 7: 1
3. Singh A, Ahmed K, Aydin A, et al. Fournier’s gangrene, a clinical review. Arch Ital Urol Androl. 2016; 88: 157-64
4. Smith GL, Bunker CB, Dinneen MD. Fournier’s gangrene. Br J Urol 1998; 81: 347-55
5. Liang SG, Chen HH, Lin SE, et al. Fournier’s gangrene in female patients. J Soc Colon Rectal Surgeon (Taiwan) 2008; 19: 57-62
6. Nisbet AA, Thompson IM. Impact of diabetes mellitus on the presentation and outcomes of Fournier’s gangrene. Urology 2002; 60: 775-9
7. Sorensen MD, Krieger JN, Rivara FP, et al. Fourneir’s gangrene: population based epidemiology and outcomes. J Urol. 2009; 181: 2120-26
8. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy. 2013; 33: 984-99
9. Invokana (package insert). Titusville, NJ: Janssen Pharmaceuticals; revised. July 2017.
10. Farxiga (Package insert). Wilmingron, DE: Astra-Zeneca Pharmaceuticals; October 2017.
11. Jardiance (package insert). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; revised. December 2017
12. Steglatro (Package insert). Whitehouse Station, NJ: Merck Sharp & Dohme, December 2017
13. Invokamet (Package insert). Boxed warning. Titusville, NJ: Janssen Pharmaceuticals; revised August 2017
14. Invokamet XR (Package insert). Boxed warning. Titusville NJ: Janssen Pharmaceuticals; January 2018
15. U.S Food and Drug Administration. FDA warns about rare occurrences of a serious infection of the genital area with SGLT-2 inhibitors for diabetes. Accessed at www.fda.gov/DrugSafety/ucm617360.htm on 22 March 2019
16. Bersoff-Match SJ, Chamberlain C, Cao C, et al. Fournier-gangrene associated with sodium-glucose cotransporter-2 inhibitors. Ann Int Med. June 2019; 170: 764-69
17. Hoffman KB, Demakas AR, Dimbil M, et al. Stimulated reporting: the impact of US food and drug administration issued alerts on the adverse event reporting system (FAERS). Drug Sa. 2014; 37: 971-80
18. The Centers for Disease Control and Prevention. Long-term trends in diabetes; April 2017. Accessed at www.cdc.gov/diabetes/statistics/slides/long_term_trends.pdf on 22 March 2019
19. The World Health Organization. Fact sheet: diabetes. Accessed at www.who.int/news.room/fact-sheets/detail/diabetes on November 8, 2018.
20. Thwaini A, Khan A, Malik A, et al. Fournier-gangrene and its emergency management. Postgraduate Med J. 2006; 82: 516-19
21. Samoski-Brocavich S, Hilas O. Canagliflozin Invokana), a novel oral agent for type 2 diabetes. PT. 2013; 38: 656-66
22. Johnson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013; 27: 479-84
23. LI Y, Burrows NR, Cregg EW, Albright A, Geiss LS. Declining rates of hospitalizations for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: U.S, 1988-2008 Diabetic Care. 2012; 35: 273-77
24. The US Food and Drug Administration, FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetic medicine canagliflozin (invokana, Invokamet, Invokamet XR). Accessed at www.fda.gov/Drugs/DrugSafety/ucm557507.htm
25. Baba M, Davis WA, Norman PE, Davis, TM, Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle Diabetes Study. Cardiovasc Diabetol. 2015; 14: 152
26. Chedid V, Vijayvargiya P, Camilleri M. Advantages and limitations of the federal adverse events reporting system in assessing adverse events reporting for eluxadoline (editorial) Clin Gastroentrol Hepatol. 2018; 16: 336-38
27. Czymek R, Kujath P, Bruch HP, et al. Treatment, outcome and quality of life after Fountier’s gangrene: a multicenter study. Colorectal Dis 2013; 15: 1529-36
28. Korkut M, Icoz G, Dayangac M, et al. Outcome analysis in patients with Fountier’s gangrene: report of 45 cases. Dis Colon Rectum. 2003; 46: 649-52
29. Eke N. Fountier’s gangrene: a review of 1726 cases. Br J Surg. 2000; 87: 718-28
30. Subramaniam D, Hureibi K, Zia K, Uheba M. The development of Fountier’s gangrene following rubber band ligation of haemorrhoids. BMJ Case Rep. 2013; 2013
31. Voelzke BB, Hagedom JC. Presentation and diagnosis of Fournier’s gangrene. Urology 2018; 114: 8-13.